PACB · Company research
Pacific Biosciences of California, Inc. (PACB): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
22records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Pacific Biosciences of California, Inc. (PACB) Stock Price, News, Quote & History - Yahoo! Finance Canada | Pacific Biosciences of California, Inc. (PACB) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors | Pacific Biosciences of California (PACB) closed at $1.99, down 2.93%, underperforming the S&P 500's 1.11% loss. Despite a 52.99% monthly gain, the company faces headwinds with expected EPS of -$0.13 (down 8.33% YoY) and revenue of $37.86 million (down 1.51% YoY). The stock holds a Zacks Rank #3 (Hold) rating with steady consensus estimates. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bearish | -1 | 1 |
| Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors - Yahoo Finance | Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics - TradingView | PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics TradingView | View source ↗ | TradingView | Oct 13, 2026 | neutral | 0 | 0.6 |
| PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics | Pacific Biosciences announced a collaboration with TychoBio to generate full-length RNA sequencing data for training AI models designed to develop RNA therapies for rare diseases. TychoBio will analyze over 10,000 samples using PacBio's HiFi and Kinnex sequencing technologies to build datasets linking RNA therapy designs to their effects, with initial focus on steric blocking antisense oligonucleotides. The partnership strengthens PacBio's presence in rare disease research and could drive demand for its sequencing platforms. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics | Pacific Biosciences announced a collaboration with TychoBio to generate full-length RNA sequencing data for training AI models designed to develop RNA therapies for rare diseases. TychoBio will analyze over 10,000 samples using PacBio's HiFi and Kinnex sequencing technologies to build datasets linking RNA therapy designs to their effects, with initial focus on steric blocking antisense oligonucleotides. The partnership strengthens PacBio's presence in rare disease research and could drive demand for its sequencing platforms. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Pacific Biosciences of California, Inc. (PACB) stock price, news, quote and history - Yahoo Finance Singapore | Pacific Biosciences of California, Inc. (PACB) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 9, 2026 | neutral | 0 | 0.6 |
| Pacific Biosciences of California, Inc. (PACB) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore | Pacific Biosciences of California, Inc. (PACB) latest stock news and headlines – Yahoo Finance Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 9, 2026 | neutral | 0 | 0.6 |
| PacBio (PACB) Stock Gets Fair Value Boost After UBS Starts Coverage Neutral - Yahoo Finance | PacBio (PACB) Stock Gets Fair Value Boost After UBS Starts Coverage Neutral Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today | Pacific Biosciences of California (PACB) fell 15.44% on October 8, 2026, significantly underperforming the S&P 500's 0.47% decline. Despite a strong 110.85% gain over the past month, the genetic analysis technology company faces headwinds with projected EPS of -$0.13 (down 8.33% YoY) and revenue expected at $37.86 million (down 1.51% YoY). The stock holds a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bearish | -1 | 1 |
| Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today | Pacific Biosciences of California (PACB) fell 15.44% on October 8, 2026, significantly underperforming the S&P 500's 0.47% decline. Despite a strong 110.85% gain over the past month, the genetic analysis technology company faces headwinds with projected EPS of -$0.13 (down 8.33% YoY) and revenue expected at $37.86 million (down 1.51% YoY). The stock holds a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bearish | -1 | 1 |
| Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today - Yahoo Finance | Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Pacific Biosciences of California (NasdaqGS:PACB) Stock Forecast & Analyst Predictions - Simply Wall Street | Pacific Biosciences of California (NasdaqGS:PACB) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 7, 2026 | neutral | 0 | 0.6 |
| Why PacBio (PACB) Stock Is Trading Up Today - Yahoo Finance | Why PacBio (PACB) Stock Is Trading Up Today Yahoo Finance | View source ↗ | Yahoo Finance | Oct 6, 2026 | neutral | 0 | 0.6 |
| Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR | The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bullish | 1 | 1 |
| Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts | Pacific Biosciences of California (PACB) stock rose 1.2% to $2.54, outperforming the S&P 500's 0.73% gain. Despite a 93.08% monthly surge, the company faces headwinds with projected EPS of -$0.13 (down 8.33% YoY) and revenue of $37.86 million (down 1.51% YoY). PACB holds a Zacks Rank of #4 (Sell) with unchanged consensus estimates over the past 30 days. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bearish | -1 | 1 |
| PACB Stock Climbs As Traders Eye Conference Catalyst - StocksToTrade | PACB Stock Climbs As Traders Eye Conference Catalyst StocksToTrade | View source ↗ | StocksToTrade | Oct 1, 2026 | neutral | 0 | 0.6 |
| Why Is PacBio (PACB) Stock Soaring Today - Yahoo Finance | Why Is PacBio (PACB) Stock Soaring Today Yahoo Finance | View source ↗ | Yahoo Finance | Sep 30, 2026 | neutral | 0 | 0.6 |
| Why PacBio (PACB) Stock Is Trading Up Today - Yahoo Finance | Why PacBio (PACB) Stock Is Trading Up Today Yahoo Finance | View source ↗ | Yahoo Finance | Sep 28, 2026 | neutral | 0 | 0.6 |
| Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance | Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know Yahoo Finance | View source ↗ | Yahoo Finance | Sep 25, 2026 | neutral | 0 | 0.6 |
| $PACB stock is up 17% today. Here's what we see in our data. - Quiver Quantitative | $PACB stock is up 17% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 25, 2026 | neutral | 0 | 0.6 |
| Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why - Yahoo Finance | Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why Yahoo Finance | View source ↗ | Yahoo Finance | Jun 12, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.